CRISPR-mediated gene editing offers the most durable suppression by permanently disrupting AREG or ADAM17 genes, leading to the sustained loss of function and robust anti-tumor effects in preclinical models with emerging epigenetic editing approaches enabling long-term silencing without permanent DNA alteration [224], potentially reducing off-target risks and improving safety for clinical translation. The gene discussed is ADAM17; the disease is neoplasm.